Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 2

3(50.0%)

Phase 1

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 2(3)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06789172Phase 1Recruiting

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Role: collaborator

NCT04410133Phase 3Completed

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

Role: collaborator

NCT04410367Phase 2Completed

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

Role: collaborator

NCT03844191Phase 1Completed

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

Role: collaborator

NCT05414422Phase 2Completed

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

Role: collaborator

NCT02963493Phase 2Completed

A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Role: collaborator

All 6 trials loaded